Addendum

Pembrolizumab (renal cell carcinoma) – Addendum to Commission A22-71

Status
Status: Commission completed
Project no.
A22-128
Last updated

Report documents

  1. Addendum

    Pembrolizumab (renal cell carcinoma) – Addendum to Commission A22-71

    published on
    Document type
    PDF document, 898 kB, EN, not accessible

Dossier assessment

Indication:

Adjuvant treatment of adult patients with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions

Result of dossier assessment:

After addendum now hint of non-quantifiable added benefit

Additional information

Federal Joint Committee (G-BA)

2023-01-19 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A22-128
Commission
Commission awarded on 06.12.2022 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Connected Projects

  1. Dossier assessment

    Pembrolizumab (renal cell carcinoma) – Benefit assessment according to § 35a SGB V

    Project no.
    A22-71
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form